2018
DOI: 10.1111/jcmm.13605
|View full text |Cite
|
Sign up to set email alerts
|

LncRNA NR2F1‐AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR‐363

Abstract: Emerging evidence has validated the vital role of long non‐coding RNA (lncRNA) in the chemoresistance of cancer treatment. In the present study, we investigate the function of lncRNA NR2F1‐AS1 on oxaliplatin (OXA) resistance of hepatocellular carcinoma (HCC) and discover the underlying molecular mechanism. Results revealed that lncRNA NR2F1‐AS1 was up‐regulated in oxaliplatin‐resistant HCC tissue and cells using microarray analysis and RT‐PCR. Meanwhile, ABCC1 protein was overexpressed in OXA‐resistant HCC cel… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

1
87
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 132 publications
(88 citation statements)
references
References 27 publications
(45 reference statements)
1
87
0
Order By: Relevance
“…MAGI2‐AS3 is another confirmed lncRNA that can suppress hepatocellular carcinoma cell proliferation and migration by acting as an endogenous sponge of miR‐374b‐5p . NR2F1‐AS1 can regulate hepatocellular carcinoma oxaliplatin resistance through targeting miR‐363‐ABCC1 pathway . In our analysis, MAGI2‐AS3 and NR2F1‐AS1 showed highly positive correlation with COL1A1 via miR‐143‐3p.…”
Section: Discussionmentioning
confidence: 53%
“…MAGI2‐AS3 is another confirmed lncRNA that can suppress hepatocellular carcinoma cell proliferation and migration by acting as an endogenous sponge of miR‐374b‐5p . NR2F1‐AS1 can regulate hepatocellular carcinoma oxaliplatin resistance through targeting miR‐363‐ABCC1 pathway . In our analysis, MAGI2‐AS3 and NR2F1‐AS1 showed highly positive correlation with COL1A1 via miR‐143‐3p.…”
Section: Discussionmentioning
confidence: 53%
“…In general, HCC tumours are genetically and phenotypically very heterogeneous as they arise from a background of different chronic pathological conditions such as liver cirrhosis and fibrosis that are most frequently associated with hepatitis B or hepatitis C virus infections, alcoholic liver diseases or metabolic disorders . Although there are various treatment strategies available, including conventional chemotherapy, surgical resection, liver transplantation and radiotherapy, the cure rate of HCC patients is very low . Besides the lack of highly reliable biomarkers to detect early‐stage tumours and the presence of primary liver diseases that limit the application of chemotherapeutics, the major reasons for poor patient outcome and high mortality rates associated with HCC are resistance to conventional anticancer therapy, a high frequency of recurrences and the formation of metastases …”
Section: Introductionmentioning
confidence: 99%
“…Although there are various treatment strategies available, including conventional chemotherapy, surgical resection, liver transplantation and radiotherapy, the cure rate of HCC patients is very low . Besides the lack of highly reliable biomarkers to detect early‐stage tumours and the presence of primary liver diseases that limit the application of chemotherapeutics, the major reasons for poor patient outcome and high mortality rates associated with HCC are resistance to conventional anticancer therapy, a high frequency of recurrences and the formation of metastases …”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Here we observe that upregulation of this gene is related to downregulation of miR-363 in this cell line, that is the first such observation. However, downregulation of miR-363 was associated with ABCC1 overexpression in oxoplatin hepatocellular carcinoma cell lines [87].…”
Section: Discussionmentioning
confidence: 91%